Kiniksa Pharmaceuticals International (KNSA) investor relations material

Executive summary

• Q2 2026 net product revenue reached $243.6 million, up 55% year-over-year, driven by ARCALYST growth in recurrent pericarditis.

• Net income for Q2 2026 was $25.4 million, compared to $17.8 million in Q2 2025.

• Raised 2026 ARCALYST net sales guidance to $980–$995 million, reflecting strong commercial momentum.

• Advanced KPL-387 to pivotal Phase 3 for recurrent pericarditis, supported by positive Phase 2 data; KPL-1161 Phase 1 trial expected by year-end.

• Maintained robust liquidity with $525.9 million in cash, cash equivalents, and short-term investments at quarter-end.

Financial highlights

• Q2 2026 ARCALYST revenue was $243.6 million, up from $156.8 million in Q2 2025, with a 55% year-over-year increase.

• Net income for Q2 2026 was $25.4 million; operating income was $27.2 million.

• Operating expenses for Q2 2026 were $216.4 million, up from $136.6 million in Q2 2025.

• Gross margin for Q2 2026 was approximately 90%.

• Cash, cash equivalents, and short-term investments totaled $525.9 million as of June 30, 2026.

Outlook and guidance

• Full-year 2026 ARCALYST revenue guidance increased to $980–$995 million, up from prior $930–$945 million.

• KPL-387 commercialization targeted for 2028–2029; KPL-1161 Phase 1 trial expected by year-end 2026.

• Current operating plan expected to remain cash flow positive on an annual basis.

• Cash and expected inflows projected to fund operations and capital expenditures for at least the next 12 months.

• Continued investment in pipeline development and global expansion through partnerships.